Search research articles
Contact Us
Filters
Showing results (151-160 of 175) with videos related to
Page
of 18
Sort By:
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
August 31, 2015
Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine
C M Nijenhuis, L Lucas, H Rosing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer
J R Kroep, G Giaccone, D A Voorn, et al.
Investigational New Drugs
|
January 24, 2017
Pharmacokinetics and excretion of <sup>14</sup>C-Plitidepsin in patients with advanced cancer
L van Andel, S Fudio, H Rosing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
M T Huizing, L J van Warmerdam, H Rosing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
V M Herben, V R Panday, D J Richel, et al.
Cancer Chemotherapy and Pharmacology
|
May 19, 2011
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
M Joerger, J A Burgers, P Baas, et al.
Investigational New Drugs
|
March 18, 2017
Human mass balance study and metabolite profiling of <sup>14</sup>C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
Lotte van Andel, Z Zhang, S Lu, et al.
Cancer Chemotherapy and Pharmacology
|
January 22, 2002
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion
C van Kesteren, R A Mathĵt, L López-Lázaro, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure
L J van Warmerdam, G J Creemers, S Rodenhuis, et al.
European Journal of Clinical Pharmacology
|
December 15, 2020
A real or apparent decrease in glomerular filtration rate in patients using olaparib?
M A C Bruin, C M Korse, B van Wijnen, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 175) with videos related to
Sort By:
Page
of 18
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
August 31, 2015
Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine
C M Nijenhuis, L Lucas, H Rosing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer
J R Kroep, G Giaccone, D A Voorn, et al.
Investigational New Drugs
|
January 24, 2017
Pharmacokinetics and excretion of <sup>14</sup>C-Plitidepsin in patients with advanced cancer
L van Andel, S Fudio, H Rosing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
M T Huizing, L J van Warmerdam, H Rosing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
V M Herben, V R Panday, D J Richel, et al.
Cancer Chemotherapy and Pharmacology
|
May 19, 2011
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
M Joerger, J A Burgers, P Baas, et al.
Investigational New Drugs
|
March 18, 2017
Human mass balance study and metabolite profiling of <sup>14</sup>C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
Lotte van Andel, Z Zhang, S Lu, et al.
Cancer Chemotherapy and Pharmacology
|
January 22, 2002
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion
C van Kesteren, R A Mathĵt, L López-Lázaro, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure
L J van Warmerdam, G J Creemers, S Rodenhuis, et al.
European Journal of Clinical Pharmacology
|
December 15, 2020
A real or apparent decrease in glomerular filtration rate in patients using olaparib?
M A C Bruin, C M Korse, B van Wijnen, et al.
Page
of 18